Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma, high-grade glioma
MONDAY, April 18, 2022 (HealthDay News) — Systemic inflammatory biomarkers may aid in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG), according to a study published online April 4 in CNS Oncology.
Tejpal Gupta, M.D., from the Homi Bhabha National Institute in Mumbai, India, and colleagues calculated systemic inflammatory indices from pretreatment complete blood counts and liver function tests and compared them against histopathology as a reference standard among 42 patients with PCNSL and 16 with HGG.
The researchers observed significant differences in the mean values for absolute lymphocyte count and prognostic nutritional index between PCNSL and HGG patients. For absolute lymphocyte count and prognostic nutritional index, the area under the receiver operating characteristic curve in the diagnosis of PCNSL was 0.70 and 0.72, respectively, indicating fair and acceptable diagnostic accuracy.
“This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging,” the authors write.
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints .jpg)
ASH Issues Guidance on Serum Ferritin Thresholds for Diagnosing Iron Deficiency 
Elevated C-Reactive Protein Linked to Increased Risk for Incident Heart Failure, All-Cause Mortality 
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists 
Better Cardiovascular Health Inversely Linked to Overactive Bladder 
